Cercet. Șt. gr. I Dr. Constantin Carolina

Cercetător Știițific gr. I Constantin Carolina
Institutul Naţional de Cercetare-Dezvoltare în Domeniul Patologiei şi Ştiinţelor Biomedicale “Victor Babeş” Bucureşti
Serviciul de Anatomie Patologică, Spitalul Clinic Colentina, Bucureşti
Interrelații microbiom-imunitate în melanomul cutanat
Autori: Carolina Constantin1,2, Elena-Georgiana Dobre1, Adriana Narcisa Munteanu1, Mihaela Surcel1, Sabina Andrada Zurac1,2,3, Monica Neagu1,2
1Laborator Imunologie, INCD “Victor Babeș”, București, România
2Serviciul Anatomie Patologică, Spitalul Clinic Colentina, București, România
3U.M.F. “Carol Davila”, București, România
Cuvinte cheie: melanom, imunitate, microbiom, citokine, obezitate
Conexiunea dintre melanomului cutanat și profilul microbiomului reprezintă un domeniu de cercetare emergent, alterări ale microbiomului fiind asociate cu inflamația cronică, eludarea imună și carcinogeneză. În melanom, răspunsul imun antitumoral și/sau răspunsul la terapie sunt mai nou interconectate cu caracteristicile microbiomului. În plus, sunt coroborate datele tot mai numeroase aduse de efectul dereglărilor metabolice (de ex., obezitate) în progresia tumorală. Astfel, obezitatea este asociată cu niveluri ridicate de adipokine cu influență asupra micromediului tumoral și a răspunsului imun. O serie de citokine susțin o stare inflamatorie cronică modulată de dezechilibrul metabolic, însa adipokinele influenteaza de asemenea tabloul inflamator în cancer. Dintre adipokine, leptina, un hormon important, poate media efectele obezității asupra progresiei melanomului, fiind implicată în modularea unor căi de semnalizare cheie (de ex., JAK2/STAT3 și MAPK cascada/FOS) și a destinului limfocitelor T prin promovarea fenotipului T helper-1. Acești modulatori solubili ai disbiozei în cancer pot fi integrați în scheme de studiu care cuprind și investigarea microbiomului, prin decelarea anumitor profiluri microbiene cu reprezentare specifică în diferitele stadii ale bolii sau ale monitorizării terapeutice. Instrumente de explorare moleculară avansată (de ex., Next Generation Sequencing NGS) pot fi inrolate în furnizarea de date rafinate pentru descrierea peisajului tumoral, într-o abordare complexă, multidimensională, a diferitelor patologii, incluzând dermato-oncologia.
Studiu finanțat de: PN 23.16.01.03/2023; ELI-RO_17/2024; COST Action CA21108.
Crosstalk between microbiome and immunity in cutaneous melanoma
Authors: Carolina Constantin1,2, Elena-Georgiana Dobre1, Adriana Narcisa Munteanu1, Mihaela Surcel1, Sabina Andrada Zurac1,2,3, Monica Neagu1,2
1Immunology Laboratory, “Victor Babeș” National Institute of Pathology, Bucharest, Romania
2Pathology Department, Colentina Clinical Hospital, Bucharest, Romania
3″Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
Keywords: melanoma, immunity, microbiome, cytokines, obesity
The connection between melanoma progression and the microbiome profile represents an emerging area of research; alterations of the microbiome occur in chronic inflammation, immune evasion, and carcinogenesis, having impact on antitumor immunity and therapeutic response. To these new approaches, the increasing data amount concerning the effect of metabolic disorders (e.g., obesity) in tumor progression are added. Thus, obesity is associated with high levels of adipokines with influence on the tumor microenvironment and immune response. A series of cytokines/chemokines supports a chronic inflammatory state modulated by metabolic imbalance, but adipokines also influence the inflammatory milieu in cancer. Recent studies suggest that among adipokines, a key hormone, leptin may mediate the effects of obesity on melanoma progression, being involved in the modulation of key signaling pathways (e.g., JAK2/STAT3 and MAPK cascade/FOS) and the fate of T lymphocytes by promoting the T helper-1 phenotype. These soluble modulators of dysbiosis in cancer can be integrated into complex protocols comprising microbiome investigation in different stages of the disease or therapeutic monitoring. Advanced molecular exploration tools (e.g., NGS) can be enlisted in providing refined data describing the tumor landscape, in a complex, multidimensional approach of different pathologies, including dermato-oncology.
Acknowledgement: PN 23.16.01.03/2023; ELI-RO_17/2024; COST Action CA21108.
Scurt CV
Carolina CONSTANTIN, Senior researcher I, PhD, biochemist, “Victor Babeș” National Institute of Pathology, Immunology Laboratory & Colentina Clinical Hospital, Research Core of Pathology Department, Bucharest. Research topics: immune parameters analysis and biomarker discovery in melanoma and non-melanoma skin cancer; co-inventor for 4 patents related to photodynamic therapy PDT in skin pathologies. Dr. Constantin conducted national research projects linked to novel photosensitizers for cancer PDT, drug-delivery nanosystems for skin regeneration; partner responsible for MNT_ERANET project 7030-1/2010 related to novel porphyrins for theranostics.
Specialization in Molecular Biology at Ludwig Institute for Cancer Research, Signal Transduction Unit (Bruxelles); Cellular Biology specialization at University of Athens, Biochemistry and Physiology Department, in the frame of NATO SfP 982838/2007 project. Technical expert in 5 EU projects for biomedical assays; teaching experience in protein microarray technology; volunteer reviewer for several ISI journals. Currently involved as MC member for COST Action CA18127 – International Nucleome Consortium (INC); MC substitute of the management committee for COST action CA16120 – European Epitranscriptomics Network (EPITRAN); alternate member of the management committee for CA18125 – Advanced Engineering and Research of Aerogels for Environment and Life Sciences (AEROGELS); membership: CA21108 European Network for Skin Engineering and Modeling (NETSKINMODELS).
Reviewer for the following Journals: Cancer Management and Research; Genes; OncoTargets and Therapy; International Journal of Nanomedicine; Nanomedicine; International Journal of General Medicine (Dove Press); Food and Chemical Toxicology (Elsevier); Evidence-Based Complementary and Alternative Medicine (Hindawi); Environmental Toxicology and Pharmacology; Seminars in Cancers; Theranostics; Frontiers in Oncology; Frontiers in Bioscience-Landmark; Journal of Pharmaceutical Research International.
Editorial Board membership: Journal of Personalized Medicine (since 2022); Revista de Chimie (Bucharest) (since 2020).
Contactează operatorul PDI 2025
Operatorul PDI 2025
Adresa: Str. A. Panu nr. 13, Iasi
Tel.: 0332.40.88.00-05
E-mail: contact@pdi.ro
Website: www.eventer.ro